Scilex shares are trading higher after the company announced the completion of its SP-103 Phase 2 study to evaluate the safety and efficacy in subjects with acute LBP.
Portfolio Pulse from Benzinga Newsdesk
Scilex Pharmaceuticals has completed its SP-103 Phase 2 study, which evaluates the safety and efficacy of its product in subjects with acute lower back pain (LBP). This has led to an increase in the company's stock price.
September 15, 2023 | 5:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex's successful completion of its SP-103 Phase 2 study has led to a rise in its stock price.
The successful completion of a Phase 2 study is a significant milestone for pharmaceutical companies, as it indicates that the product under study has shown promising results in terms of safety and efficacy. This positive news has led to an increase in investor confidence, resulting in a rise in Scilex's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100